ZyVersa Therapeutics, Inc.
ZVSA
$0.18
-$0.02-11.21%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 6.42M | 6.52M | 6.93M | 7.36M | 7.71M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.58M | 7.74M | 8.45M | 9.14M | 9.63M |
| Operating Income | -7.58M | -7.74M | -8.45M | -9.14M | -9.63M |
| Income Before Tax | -26.55M | -8.29M | -8.84M | -9.41M | -21.92M |
| Income Tax Expenses | -854.70K | -3.00K | 6.70K | 6.70K | -586.40K |
| Earnings from Continuing Operations | -25.70 | -8.29 | -8.84 | -9.41 | -21.33 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -25.70M | -8.29M | -8.84M | -9.41M | -21.33M |
| EBIT | -7.58M | -7.74M | -8.45M | -9.14M | -9.63M |
| EBITDA | -7.57M | -7.74M | -8.45M | -9.13M | -9.62M |
| EPS Basic | -4.46 | -4.33 | -7.18 | -10.99 | -72.35 |
| Normalized Basic EPS | -1.35 | -2.71 | -4.48 | -6.86 | -11.58 |
| EPS Diluted | -4.46 | -4.33 | -7.18 | -10.99 | -72.35 |
| Normalized Diluted EPS | -1.35 | -2.71 | -4.48 | -6.86 | -11.58 |
| Average Basic Shares Outstanding | 17.65M | 10.90M | 6.92M | 4.44M | 2.66M |
| Average Diluted Shares Outstanding | 17.65M | 10.90M | 6.92M | 4.44M | 2.66M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |